1. Apple receives US approval for blood oxygen feature in watches. 2. Users can monitor levels on Apple Watch Series 9, 10, and Ultra 2. 3. Legal disputes with Masimo over pulse oximetry technology continue. 4. Masimo's legal victories previously halted imports of some Apple watches. 5. Apple previously removed pulse oximetry from US models amid patent issues.
The reintroduction of the blood oxygen feature can enhance Apple's wearables offerings, boosting user engagement. Previous instances show that new features positively impacted Apple's stock. For example, when Apple introduced health features, stock prices experienced upward trends.
The approval allows Apple to strengthen its competitive edge in the wearables market. This development addresses legal challenges while enhancing product utility, which is crucial for Apple’s brand value.
The immediate release of a sought-after feature will likely drive quick consumer interest. Historically, similar updates have led to an immediate uptick in sales and stock performance.